Structure Therapeutics (GPCR) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Clinical priorities and timing

• Global phase III ACCOMPLISH-1 and ACCOMPLISH-2 are underway for aleniglipron; recruitment, retention and study quality are priorities, with data expected at the end of 2028.

• ACCG-2671 entered a 12-week phase IIa multiple-ascending-dose (MAD) study; results are expected in H1 next year.

• Q4 readouts are planned for aleniglipron body composition, type 2 diabetes and a switch study from injectable therapy.

• ACCG-3535, a second DACRA molecule, is expected to enter the clinic by year-end; a GLP-1/GIP program is also planned to enter the clinic by year-end.

Oral obesity market and small molecules

• Oral Wegovy and Foundayo had captured 17% of the GLP-1 market; 80% of their users were new entrants, and oral GLP-1s are projected to reach 50% of the market by 2030.

• Small molecules were positioned as a way to improve access through affordability, manufacturing scale and no cold-chain requirements, while offering an oral option to patients who prefer not to use injections.

Amylin program update

• First human data for oral DACRA ACCG-2671 showed a six-day half-life, enabling exploration of daily and weekly dosing; 3-month toxicology was clean, with no SAEs or liver-toxicity signals reported.

• Exploratory weight loss was 3.3% at 10 mg; CTX-I and bone alkaline phosphatase moved in directions interpreted as supporting improved bone health.

• The 12-week MAD study will explore dose levels and daily and exploratory weekly schedules, balancing efficacy and tolerability; dosing schedules may be adapted as evidence emerges.

• Six- and nine-month toxicology studies are underway; parallel discovery continues on DACRA and selective amylin receptor agonist (SARA) molecules.

• ACCG-3535 and other amylin chemistry are intended to broaden the portfolio and improve the probability of success; a broad small-molecule amylin IP portfolio is being developed.